Cancer Care Ontario | Cancer Care Ontario

21 Results

Guidelines and Advice

Consensus-based organizational guideline for the planning and delivery of spine stereotactic body radiotherapy treatment in Ontario

Status: Current
ID: GL 21-6

Apr 2023

Guidelines and Advice

Cancer Care Ontario Bladder Cancer Guideline: An Endorsement of the 2017 American Urological Association Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA, ASCO, ASTRO, SUO Guide

Status: In-Review
ID: GL-END 3-21

Jan 2018

Guidelines and Advice

Computerized Prescriber Order Entry (CPOE) in the Outpatient Oncology Setting

Status: Current
ID: 12-14

May 2012

Guidelines and Advice

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Status: Current
ID: GL 4-18
Version: N/A

Sep 2020

Guidelines and Advice

Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum

Status: Current
ID: GL 3-20
Version: N/A

Aug 2019

Guidelines and Advice

Cannabis and cannabinoids: Cancer risk and use to manage cancer symptoms

Status: Current
ID: N/A
Version: 2

Jan 2023

Guidelines and Advice

Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus

Status: Education and Information
ID: 2-12
Version: 2

Oct 2013

Guidelines and Advice

Continuous versus Intermittent Chemotherapy Strategies in Inoperable, Advanced Colorectal Cancer

Status: Current
ID: 2-6
Version: 2

Sep 2022

Guidelines and Advice

Clinical Utility of Positron Emission Tomography in the Diagnosis, Staging and Management of Sarcoidosis

Status: Current
ID: PET 11

Aug 2011

Guidelines and Advice

Chemotherapy (i.e., Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) for Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma

Status: Archived
ID: GL 11-11

Jul 2012

Guidelines and Advice

Capecitabine in Stage IV Breast Cancer

Status: Archived
ID: 1-16
Version: 2

Sep 2011

Guidelines and Advice

Chemotherapy or Radiotherapy for Resectable Pancreatic Adenocarcinoma

Status: Archived
ID: 2-23
Version: 2-23 Version 2

Oct 2015

Consensus-based organizational guideline for the planning and delivery of spine stereotactic body radiotherapy treatment in Ontario

Cancer Care Ontario Bladder Cancer Guideline: An Endorsement of the 2017 American Urological Association Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA, ASCO, ASTRO, SUO Guide

Computerized Prescriber Order Entry (CPOE) in the Outpatient Oncology Setting

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum

Cannabis and cannabinoids: Cancer risk and use to manage cancer symptoms

Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus

Continuous versus Intermittent Chemotherapy Strategies in Inoperable, Advanced Colorectal Cancer

Clinical Utility of Positron Emission Tomography in the Diagnosis, Staging and Management of Sarcoidosis

Chemotherapy (i.e., Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) for Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma

Capecitabine in Stage IV Breast Cancer

Chemotherapy or Radiotherapy for Resectable Pancreatic Adenocarcinoma

Pages